Prescription Drug Prices:
Analysis of Canada's Patented Medicine Prices Review Board
HRD-93-51: Published: Feb 17, 1993. Publicly Released: Feb 22, 1993.
Additional Materials:
- Full Report:
Contact:
Pursuant to a congressional request, GAO: (1) described the purpose and structure of Canada's Patented Medicine Prices Review Board as well as its guidelines and procedures, especially those used to determine if a drug price is excessive; and (2) summarized the evidence about the effects of the Board's actions on the prices of new drugs, on price increases for existing drugs, and on pharmaceutical research and development.
GAO found that: (1) the Board is the federal body responsible for restraining prescription drug prices in Canada; (2) the Board periodically publishes guidelines that it uses to determine whether a manufacturer's introductory price on a new drug or price increase on an older patented drug is excessive; (3) the Board has the power to order the removal of market exclusivity or a price reduction if it finds a price to be excessive; (4) Canadian experience shows that a drug price review board can restrain prescription drug prices; (5) statistical analyses suggest that Canadian prices of new patented drugs subject to Board review were, on average, one-third lower than had there been no Board; and (6) restraint of drug prices reduces the incentive for manufacturers to undertake innovative pharmaceutical research and development.
Aug 14, 2019
Social Security and Medicare:
Improved Schedule Management Needed for More Timely Trust Fund ReportsGAO-19-596: Published: Jul 30, 2019. Publicly Released: Aug 14, 2019.
Aug 13, 2019
-
Medicare Part D:
Use of Pharmacy Benefit Managers and Efforts to Manage Drug Expenditures and UtilizationGAO-19-498: Published: Jul 15, 2019. Publicly Released: Aug 13, 2019.
Aug 9, 2019
-
Medicaid Payment:
CMS Has Not Overseen States' Implementation of Changes to Third-Party LiabilityGAO-19-601: Published: Aug 9, 2019. Publicly Released: Aug 9, 2019. -
Obesity Drugs:
Few Adults Used Prescription Drugs for Weight Loss and Insurance Coverage VariedGAO-19-577: Published: Aug 9, 2019. Publicly Released: Aug 9, 2019.
Aug 7, 2019
-
Generic Drug Applications:
FDA Should Take Additional Steps to Address Factors That May Affect Approval Rates in the First Review CycleGAO-19-565: Published: Aug 7, 2019. Publicly Released: Aug 7, 2019.
Jul 31, 2019
-
Medicare Physician Services:
Spending On and Use of Billing Codes for Comprehensive Care Planning ServicesGAO-19-557: Published: Jul 31, 2019. Publicly Released: Jul 31, 2019.
Jul 30, 2019
-
Medicare Plan Finder:
Usability Problems and Incomplete Information Create Challenges for Beneficiaries Comparing Coverage OptionsGAO-19-627: Published: Jul 26, 2019. Publicly Released: Jul 30, 2019.
Jul 29, 2019
-
Medicaid:
States' Use and Distribution of Supplemental Payments to HospitalsGAO-19-603: Published: Jul 19, 2019. Publicly Released: Jul 29, 2019.
Jul 25, 2019
-
Electronic Health Records:
VA Needs to Identify and Report Existing System CostsGAO-19-679T: Published: Jul 25, 2019. Publicly Released: Jul 25, 2019. -
Electronic Health Records:
VA Needs to Identify and Report System CostsGAO-19-125: Published: Jul 25, 2019. Publicly Released: Jul 25, 2019.
Looking for more? Browse all our products here
Explore our Key Issues on Health Care
- Air Quality
- Elder Abuse
- Federal Efforts to Prevent Drug Misuse
- Health Care Quality
- Health Information Technology
- Improving Federal Programs that Serve Tribes and Their Members - High Risk Issue
- Managing Risks and Improving VA Health Care
- Medicaid - High Risk Issue
- Medical Product Oversight - High Risk Issue
- Medicare - High Risk Issue
- Prescription Drug Spending
- Reducing Government-wide Improper Payments
- Supports and Services for Transitioning Veterans
- Toxic Chemicals - High Risk Issue
- VA and DOD Health Care Management
- VA and DOD Patient Care
Explore our other Key Issues here
